Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2- advanced breast cancer

匹配调整后的间接比较研究，比较瑞博西尼联合来曲唑与帕博西尼联合来曲唑作为HR+/HER2-晚期乳腺癌一线治疗方案的无进展生存期（PFS）和总生存期（OS）。